40 results on '"Halabi, Susan"'
Search Results
2. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
- Author
-
Lopes, Renato D, Higano, Celestia S, Slovin, Susan F, Nelson, Adam J, Bigelow, Robert, Sørensen, Per S, Melloni, Chiara, Goodman, Shaun G, Evans, Christopher P, Nilsson, Jan, Bhatt, Deepak L, Clarke, Noel W, Olesen, Tine K, Doyle-Olsen, Belinda T, Kristensen, Henriette, Arney, Lauren, Roe, Matthew T, Alexander, John H, Mol-Arts, Mirjam, Mansor-Lefebvre, Samreen, Zubovskiy, Konstantin, Blemings, Allan, Dugi, Klaus, Bloomfield, Gerald, Kontos, Chris, DeVore, Adam, Jordan, Dedrick, Kolls, Bradley, Matthews, Robin, Mehta, Rajendra, Povsic, Thomas J, Morse, Michael, Mahaffey, Kenneth W, Halabi, Susan, Leong, Darryl, Klotz, Laurence, Fleshner, Neil, Jansz, Godfrey, Giddens, Jonathan, Egerdie, Russell, Chin, Joseph, Zadra, Joseph, Casey, Richard, Simard, Jean, Niazi, Tamim, Martin, André-Guy, Babjuk, Marek, Hajek, Jaroslav, Klecka, Jiri, Kubes, Jiri, Schraml, Jan, Jakesova, Jitka, Vanasek, Jaroslav, Melichar, Bohuslav, Seikkula, Heikki, Abdiche, Manouar Samir, Colombel, Marc, Debourdeau, Philippe, Robert, Gregoire, Villers, Arnauld, Ploussard, Guillaume, Pradere, Benjamin, Bruyere, Franck, Descotes, Jean-Luc, Ouzaid, Idir, Winter, Alexander, Hanitzsch, Herbert, Sperling, Herbert, Eckert, Ralf, Hammerer, Peter, Stagge, Elke, Seseke, Florian, Szymula, Silvio, Bamias, Aristotelis, Thanos, Anastasios, Hatzimouratidis, Konstantinos, Mamoulakis, Charalambos, Kalofonos, Haralabos, Oszukowska, Elzbieta, Madziarska, Katarzyna, Fijuth, Jacek, Obarzanowski, Mateusz, Alekseev, Boris, Atduev, Vagif, Pushkar, Dmitri, Veliev, Evgeniy, Zyryanov, Alexander, Petrov, Sergey, Kopyltsov, Evgeny, Kozlov, Vadim, Macko, Ladislav, Dubravicky, Jozef, Polak, Richard, Mir, Obaidullah, Vargovcak, Marek, Mincik, Ivan, Kliment, Jan, Goncalves, Frederico, Mikulas, Juraj, and Sokol, Roman
- Subjects
Cancer ,Clinical Trials and Supportive Activities ,Patient Safety ,Aging ,Prostate Cancer ,Urologic Diseases ,Cardiovascular ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Aged ,Humans ,Leuprolide ,Male ,Oligopeptides ,Prospective Studies ,Prostatic Neoplasms ,agonists ,atherosclerosis ,cardiotoxicity ,drug therapy ,gonadotropin-releasing hormone ,prostatic neoplasms ,PRONOUNCE Study Investigators ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Public Health and Health Services ,Cardiovascular System & Hematology - Abstract
BackgroundThe relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial.MethodsIn this international, multicenter, prospective, randomized, open-label trial, men with prostate cancer and concomitant atherosclerotic cardiovascular disease were randomly assigned 1:1 to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide for 12 months. The primary outcome was the time to first adjudicated major adverse cardiovascular event (composite of death, myocardial infarction, or stroke) through 12 months.ResultsBecause of slower-than-projected enrollment and fewer-than-projected primary outcome events, enrollment was stopped before the 900 planned participants were accrued. From May 3, 2016, to April 16, 2020, a total of 545 patients from 113 sites across 12 countries were randomly selected. Baseline characteristics were balanced between study groups. The median age was 73 years, 49.8% had localized prostate cancer; 26.3% had locally advanced disease, and 20.4% had metastatic disease. A major adverse cardiovascular event occurred in 15 (5.5%) patients assigned to degarelix and 11 (4.1%) patients assigned to leuprolide (hazard ratio, 1.28 [95% CI, 0.59-2.79]; P=0.53).ConclusionsPRONOUNCE (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease) is the first, international, randomized clinical trial to prospectively compare the cardiovascular safety of a GnRH antagonist and a GnRH agonist in patients with prostate cancer. The study was terminated prematurely because of the smaller than planned number of participants and events, and no difference in major adverse cardiovascular events at 1 year between patients assigned to degarelix or leuprolide was observed. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02663908.
- Published
- 2021
3. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
- Author
-
Eastham, James A, Heller, Glenn, Halabi, Susan, Monk, J Paul, Beltran, Himisha, Gleave, Martin, Evans, Christopher P, Clinton, Steven K, Szmulewitz, Russell Z, Coleman, Jonathan, Hillman, David W, Watt, Colleen R, George, Saby, Sanda, Martin G, Hahn, Olwen M, Taplin, Mary-Ellen, Parsons, J Kellogg, Mohler, James L, Small, Eric J, and Morris, Michael J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prostate Cancer ,Patient Safety ,Urologic Diseases ,Cancer ,Adenocarcinoma ,Adult ,Aged ,Aged ,80 and over ,Androgen Antagonists ,Antineoplastic Combined Chemotherapy Protocols ,Chemotherapy ,Adjuvant ,Disease Progression ,Docetaxel ,Humans ,Male ,Middle Aged ,Neoadjuvant Therapy ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Progression-Free Survival ,Prostatectomy ,Prostatic Neoplasms ,Risk Assessment ,Risk Factors ,Time Factors ,United States ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposeRadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression-free survival (BPFS) over RP alone.Patients and methodsMen with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS).ResultsIn total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone.ConclusionThe primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.
- Published
- 2020
4. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
- Author
-
Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bjartell, Anders, Bossi, Alberto, Briganti, Alberto, Bristow, Rob G, Chi, Kim N, Clarke, Noel, Davis, Ian D, de Bono, Johann, Drake, Charles G, Duran, Ignacio, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Heinrich, Daniel, Higano, Celestia Tia S, Hofman, Michael S, Hussain, Maha, James, Nicolas, Kanesvaran, Ravindran, Kantoff, Philip, Khauli, Raja B, Leibowitz, Raya, Logothetis, Chris, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chris, Poon, Darren MC, Pritchard, Colin C, Reiter, Robert E, Roach, Mack, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I, Shore, Neal, Small, Eric, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Steuber, Thomas, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tombal, Bertrand, Türkeri, Levent, van Oort, Inge, Zapatero, Almudena, and Omlin, Aurelius
- Subjects
Cancer ,Urologic Diseases ,Aging ,Prostate Cancer ,Good Health and Well Being ,Bone Neoplasms ,Humans ,Male ,Neoplasm Metastasis ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Practice Guidelines as Topic ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Advanced prostate cancer ,High-risk localised prostate cancer ,Hormone-sensitive prostate cancer ,Castration-resistant prostate cancer ,Oligometastatic prostate cancer ,Progression-free survival ,Overall survival ,Prostate cancer treatment ,Imaging ,Genetics ,Tumour genomic profiling ,Castration-naïve prostate cancer ,Clinical Sciences ,Urology & Nephrology - Abstract
BackgroundInnovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.ObjectiveTo present the results from the APCCC 2019.Design, setting, and participantsSimilar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process.Results and limitationsPanellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material.ConclusionsThese voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials.Patient summaryThe Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.
- Published
- 2020
5. Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality
- Author
-
Dess, Robert T, Hartman, Holly E, Mahal, Brandon A, Soni, Payal D, Jackson, William C, Cooperberg, Matthew R, Amling, Christopher L, Aronson, William J, Kane, Christopher J, Terris, Martha K, Zumsteg, Zachary S, Butler, Santino, Osborne, Joseph R, Morgan, Todd M, Mehra, Rohit, Salami, Simpa S, Kishan, Amar U, Wang, Chenyang, Schaeffer, Edward M, Roach, Mack, Pisansky, Thomas M, Shipley, William U, Freedland, Stephen J, Sandler, Howard M, Halabi, Susan, Feng, Felix Y, Dignam, James J, Nguyen, Paul L, Schipper, Matthew J, and Spratt, Daniel E
- Subjects
Prostate Cancer ,Prevention ,Aging ,Clinical Trials and Supportive Activities ,Urologic Diseases ,Clinical Research ,Cancer ,Patient Safety ,Good Health and Well Being ,Black or African American ,Aged ,Cause of Death ,Humans ,Male ,Middle Aged ,Prostatic Neoplasms ,SEER Program ,United States ,United States Department of Veterans Affairs ,Oncology and Carcinogenesis ,Public Health and Health Services - Abstract
ImportanceBlack men are more likely to die of prostate cancer than white men. In men with similar stages of disease, the contribution of biological vs nonbiological differences to this observed disparity is unclear.ObjectiveTo quantify the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer.Design, setting, and participantsThis multiple-cohort study included updated individual patient-level data of men with clinical T1-4N0-1M0 prostate cancer from the following 3 cohorts: Surveillance, Epidemiology, and End Results (SEER [n = 296 273]); 5 equal-access regional medical centers within the Veterans Affairs health system (VA [n = 3972]); and 4 pooled National Cancer Institute-sponsored Radiation Therapy Oncology Group phase 3 randomized clinical trials (RCTs [n = 5854]). Data were collected in the 3 cohorts from January 1, 1992, through December 31, 2013, and analyzed from April 27, 2017, through April 13, 2019.ExposuresIn the VA and RCT cohorts, all patients received surgery and radiotherapy, respectively, with curative intent. In SEER, radical treatment, hormone therapy, or conservative management were received.Main outcomes and measuresProstate cancer-specific mortality (PCSM). Secondary measures included other-cause mortality (OCM). To adjust for demographic-, cancer-, and treatment-related baseline differences, inverse probability weighting (IPW) was performed.ResultsAmong the 306 100 participants included in the analysis (mean [SD] age, 64.9 [8.9] years), black men constituted 52 840 patients (17.8%) in the SEER cohort, 1513 (38.1%) in the VA cohort, and 1129 (19.3%) in the RCT cohort. Black race was associated with an increased age-adjusted PCSM hazard (subdistribution hazard ratio [sHR], 1.30; 95% CI, 1.23-1.37; P
- Published
- 2019
6. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- Author
-
Gillessen, Silke, Attard, Gerhardt, Beer, Tomasz M, Beltran, Himisha, Bossi, Alberto, Bristow, Rob, Carver, Brett, Castellano, Daniel, Chung, Byung Ha, Clarke, Noel, Daugaard, Gedske, Davis, Ian D, de Bono, Johann, dos Reis, Rodolfo Borges, Drake, Charles G, Eeles, Ros, Efstathiou, Eleni, Evans, Christopher P, Fanti, Stefano, Feng, Felix, Fizazi, Karim, Frydenberg, Mark, Gleave, Martin, Halabi, Susan, Heidenreich, Axel, Higano, Celestia S, James, Nicolas, Kantoff, Philip, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B, Kramer, Gero, Logothetis, Chris, Maluf, Fernando, Morgans, Alicia K, Morris, Michael J, Mottet, Nicolas, Murthy, Vedang, Oh, William, Ost, Piet, Padhani, Anwar R, Parker, Chris, Pritchard, Colin C, Roach, Mack, Rubin, Mark A, Ryan, Charles, Saad, Fred, Sartor, Oliver, Scher, Howard, Sella, Avishay, Shore, Neal, Smith, Matthew, Soule, Howard, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Tannock, Ian, Tombal, Bertrand, Valdagni, Riccardo, Wiegel, Thomas, and Omlin, Aurelius
- Subjects
Cancer ,Urologic Diseases ,Aging ,Prostate Cancer ,Good Health and Well Being ,Humans ,Male ,Neoplasm Staging ,Practice Guidelines as Topic ,Prostatic Neoplasms ,Advanced and high-risk localized prostate cancer ,Castration-naive and castration-resistant prostate cancer ,Therapeutics ,Consensus ,Oligometastatic prostate cancer ,Clinical Sciences ,Urology & Nephrology - Abstract
BackgroundIn advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.ObjectiveTo present the report of APCCC 2017.Design, setting, and participantsTen important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions.Outcome measurements and statistical analysisThe panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process.Results and limitationsVoting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data.ConclusionsThe presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them.Patient summaryThe second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.
- Published
- 2018
7. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
- Author
-
Xie, Wanling, Regan, Meredith M, Buyse, Marc, Halabi, Susan, Kantoff, Philip W, Sartor, Oliver, Soule, Howard, Clarke, Noel W, Collette, Laurence, Dignam, James J, Fizazi, Karim, Paruleker, Wendy R, Sandler, Howard M, Sydes, Matthew R, Tombal, Bertrand, Williams, Scott G, Sweeney, Christopher J, and Group, on behalf of the ICECaP Working
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Clinical Trials and Supportive Activities ,Prostate Cancer ,Clinical Research ,Prevention ,Urologic Diseases ,Cancer ,Combined Modality Therapy ,Disease-Free Survival ,Endpoint Determination ,Humans ,Male ,Neoplasm Metastasis ,Prostatic Neoplasms ,Randomized Controlled Trials as Topic ,Risk Factors ,Survival Analysis ,ICECaP Working Group ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By June 2013, 102 completed or ongoing randomized trials were identified and individual patient data were collected from 28 trials with 28,905 patients. Disease-free survival (DFS) and metastasis-free survival (MFS) were determined for 21,140 patients from 24 trials and 12,712 patients from 19 trials, respectively. We evaluated the surrogacy of DFS and MFS for OS by using a two-stage meta-analytic validation model by determining the correlation of an intermediate clinical end point with OS and the correlation of treatment effects on both the intermediate clinical end point and OS. Results Trials enrolled patients from 1987 to 2011. After a median follow-up of 10 years, 45% of 21,140 men and 45% of 12,712 men experienced a DFS and MFS event, respectively. For DFS and MFS, 61% and 90% of the patients, respectively, were from radiation trials, and 63% and 66%, respectively, had high-risk disease. At the patient level, Kendall's τ correlation with OS was 0.85 and 0.91 for DFS and MFS, respectively. At the trial level, R2 was 0.86 (95% CI, 0.78 to 0.90) and 0.83 (95% CI, 0.71 to 0.88) from weighted linear regression of 8-year OS rates versus 5-year DFS and MFS rates, respectively. Treatment effects-measured by log hazard ratios-for the surrogates and OS were well correlated ( R2, 0.73 [95% CI, 0.53 to 0.82] for DFS and 0.92 [95% CI, 0.81 to 0.95] for MFS). Conclusion MFS is a strong surrogate for OS for localized prostate cancer that is associated with a significant risk of death from prostate cancer.
- Published
- 2017
8. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
- Author
-
Smith, Matthew R, Halabi, Susan, Ryan, Charles J, Hussain, Arif, Vogelzang, Nicholas, Stadler, Walter, Hauke, Ralph J, Monk, J Paul, Saylor, Philip, Bhoopalam, Nirmala, Saad, Fred, Sanford, Ben, Kelly, W Kevin, Morris, Michael, and Small, Eric J
- Subjects
Clinical Research ,Prevention ,Clinical Trials and Supportive Activities ,Aging ,Prostate Cancer ,Urologic Diseases ,Cancer ,Patient Safety ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adenocarcinoma ,Aged ,Androgen Antagonists ,Bone Density Conservation Agents ,Bone Neoplasms ,Diagnostic Imaging ,Diphosphonates ,Disease Progression ,Humans ,Imidazoles ,Male ,Orchiectomy ,Prostatic Neoplasms ,Treatment Outcome ,Zoledronic Acid ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeZoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases but its role earlier in the natural history of the disease is unknown. This phase III study evaluated the efficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metastatic prostate cancer.Patients and methodsMen with castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a placebo. After their disease progressed to castration-resistant status, all patients received open-label treatment with zoledronic acid. The primary end point was time to first SRE, defined as radiation to bone, clinical fracture, spinal cord compression, surgery to bone, or death as a result of prostate cancer. Target accrual was 680 patients. Primary analysis was planned after 470 SREs. The study was discontinued prematurely (645 patients; 299 SREs) after the corporate supporter withdrew study drug supply.ResultsEarly zoledronic acid was not associated with increased time to first SRE. The median time to first SRE was 31.9 months in the zoledronic acid group (95% CI, 24.2 to 40.3) and 29.8 months in the placebo group (95% CI, 25.3 to 37.2; hazard ratio, 0.97; 95% CI, 0 to 1.17; one-sided stratified log-rank P = .39). Overall survival was similar between the groups (hazard ratio, 0.88; 95% CI, 0.70 to 1.12; P = .29). Rates of adverse events were similar between the groups.ConclusionIn men with castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid was not associated with lower risk for SREs.
- Published
- 2014
9. Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- Author
-
Halabi, Susan, Lin, Chen-Yen, Kelly, W Kevin, Fizazi, Karim S, Moul, Judd W, Kaplan, Ellen B, Morris, Michael J, and Small, Eric J
- Subjects
Cancer ,Urologic Diseases ,Clinical Research ,Prostate Cancer ,Aged ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Bevacizumab ,Biomarkers ,Tumor ,Clinical Trials ,Phase III as Topic ,Docetaxel ,Germany ,Humans ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Nomograms ,Orchiectomy ,Predictive Value of Tests ,Prednisone ,Prognosis ,Proportional Hazards Models ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Random Allocation ,Reproducibility of Results ,Risk Assessment ,Risk Factors ,Taxoids ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposePrognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and validated an updated prognostic model to predict OS in patients receiving first-line chemotherapy.MethodsData from a phase III trial of 1,050 patients with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]). The data were randomly split into training and testing sets. A separate phase III trial served as an independent validation set. Adaptive least absolute shrinkage and selection operator selected eight factors prognostic for OS. A predictive score was computed from the regression coefficients and used to classify patients into low- and high-risk groups. The model was assessed for its predictive accuracy using the time-dependent area under the curve (tAUC).ResultsThe model included Eastern Cooperative Oncology Group performance status, disease site, lactate dehydrogenase, opioid analgesic use, albumin, hemoglobin, prostate-specific antigen, and alkaline phosphatase. Median OS values in the high- and low-risk groups, respectively, in the testing set were 17 and 30 months (hazard ratio [HR], 2.2; P < .001); in the validation set they were 14 and 26 months (HR, 2.9; P < .001). The tAUCs were 0.73 (95% CI, 0.70 to 0.73) and 0.76 (95% CI, 0.72 to 0.76) in the testing and validation sets, respectively.ConclusionAn updated prognostic model for OS in patients with mCRPC receiving first-line chemotherapy was developed and validated on an external set. This model can be used to predict OS, as well as to better select patients to participate in trials on the basis of their prognosis.
- Published
- 2014
10. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.
- Author
-
Vandekerkhove, Gillian, Giri, Veda N., Halabi, Susan, McNair, Christopher, Hamade, Khaldoun, Bitting, Rhonda L., and Wyatt, Alexander W.
- Subjects
MEDICAL personnel ,PROSTATE cancer ,CELL-free DNA ,DNA repair ,DNA damage ,RESEARCH personnel - Abstract
Clinical genomic testing of patient germline, tumor tissue, or plasma cell-free DNA can enable a personalized approach to cancer management and treatment. In prostate cancer (PCa), broad genotyping tests are now widely used to identify germline and/or somatic alterations in BRCA2 and other DNA damage repair genes. Alterations in these genes can confer cancer sensitivity to poly (ADP-ribose) polymerase inhibitors, are linked with poor prognosis, and can have potential hereditary cancer implications for family members. However, there is huge variability in genomic tests and reporting standards, meaning that for successful implementation of testing in clinical practice, end users must carefully select the most appropriate test for a given patient and critically interpret the results. In this white paper, we outline key pre- and post-test considerations for choosing a genomic test and evaluating reported variants, specifically for patients with advanced PCa. Test choice must be based on clinical context and disease state, availability and suitability of tumor tissue, and the genes and regions that are covered by the test. We describe strategies to recognize false positives or negatives in test results, including frameworks to assess low tumor fraction, subclonal alterations, clonal hematopoiesis, and pathogenic versus nonpathogenic variants. We assume that improved understanding among health care professionals and researchers of the nuances associated with genomic testing will ultimately lead to optimal patient care and clinical decision making. This article provides a helpful framework for choosing and interpreting a genomic test in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
- Author
-
Halabi, Susan, Lin, Chen-Yen, Small, Eric J, Armstrong, Andrew J, Kaplan, Ellen B, Petrylak, Daniel, Sternberg, Cora N, Shen, Liji, Oudard, Stephane, de Bono, Johann, and Sartor, Oliver
- Subjects
Clinical Research ,Prostate Cancer ,Cancer ,Urologic Diseases ,Aged ,Alkaline Phosphatase ,Antineoplastic Combined Chemotherapy Protocols ,Area Under Curve ,Biomarkers ,Tumor ,Docetaxel ,Drug Administration Schedule ,Hemoglobins ,Humans ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Mitoxantrone ,Models ,Statistical ,Multivariate Analysis ,Nomograms ,Organoplatinum Compounds ,Pain ,Predictive Value of Tests ,Prednisone ,Prognosis ,Proportional Hazards Models ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Castration-Resistant ,Sensitivity and Specificity ,Taxoids ,Treatment Outcome ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundSeveral prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS in men who had progressed after first-line chemotherapy and were selected to receive second-line chemotherapy.MethodsData from a phase III trial in men with mCRPC who had developed progressive disease after first-line chemotherapy (TROPIC trial) were used. The TROPIC was randomly split into training (n = 507) and testing (n = 248) sets. Another dataset consisting of 488 men previously treated with docetaxel (SPARC trial) was used for external validation. Adaptive least absolute shrinkage and selection operator selected nine prognostic factors of OS. A prognostic score was computed from the regression coefficients. The model was assessed on the testing and validation sets for its predictive accuracy using the time-dependent area under the curve (tAUC).ResultsThe nine prognostic variables in the final model were Eastern Cooperative Oncology Group performance status, time since last docetaxel use, measurable disease, presence of visceral disease, pain, duration of hormonal use, hemoglobin, prostate specific antigen, and alkaline phosphatase. The tAUCs for this model were 0.73 (95% confidence interval [CI] = 0.72 to 0.74) and 0.70 (95% CI = 0.68 to 0.72) for the testing and validation sets, respectively.ConclusionsA prognostic model of OS in the postdocetaxel, second-line chemotherapy, mCRPC setting was developed and externally validated. This model incorporates novel prognostic factors and can be used to provide predicted probabilities for individual patients and to select patients to participate in clinical trials on the basis of their prognosis. Prospective validation is needed.
- Published
- 2013
12. Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
- Author
-
Halabi, Susan, Armstrong, Andrew J, Sartor, Oliver, de Bono, Johann, Kaplan, Ellen, Lin, Chen-Yen, Solomon, Nicole C, and Small, Eric J
- Subjects
Clinical Research ,Cancer ,Aging ,Urologic Diseases ,Prostate Cancer ,Aged ,Androgen Antagonists ,Antineoplastic Agents ,Antineoplastic Agents ,Hormonal ,Drug Resistance ,Neoplasm ,Humans ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Mitoxantrone ,Neoplasm Metastasis ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Castration-Resistant ,Taxoids ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeProstate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy.Patients and methodsData from a phase III trial of patients with mCRPC randomly assigned to cabazitaxel plus prednisone (C + P) or mitoxantrone plus prednisone were used. PSA decline (≥ 30% and ≥ 50%), velocity, and rise within the first 3 months of treatment were evaluated as surrogates for OS. The Prentice criteria, proportion of treatment explained (PTE), and meta-analytic approaches were used as measures of surrogacy.ResultsThe observed hazard ratio (HR) for death for patients treated with C + P was 0.66 (95% CI, 0.55 to 0.79; P < .001). Furthermore, a ≥ 30% decline in PSA was a statistically significant predictor of OS (HR for death, 0.52; 95% CI, 0.43 to 0.64; P < .001). Adjusting for treatment effect, the HR for a ≥ 30% PSA decline was 0.50 (95% CI, 0.40 to 0.62; P < .001), but treatment remained statistically significant, thus failing the third Prentice criterion. The PTE for a ≥ 30% decline in PSA was 0.34 (95% CI, 0.11 to 0.56), indicating a lack of surrogacy for OS. The values of R(2) were < 1, suggesting that PSA decline was not surrogate for OS.ConclusionSurrogacy for any PSA-based end point could not be demonstrated in this analysis. Thus, the benefits of cabazitaxel in mediating a survival benefit are not fully captured by early PSA changes.
- Published
- 2013
13. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer
- Author
-
Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F, Millard, Frederick, Stadler, Walter M, Morris, Michael J, Kantoff, Philip, Monk, J Paul, Carducci, Michael, Small, Eric J, and Oncology, for the Alliance for Clinical Trials in
- Subjects
Prostate Cancer ,Clinical Research ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,Androgen Antagonists ,Antibodies ,Monoclonal ,Humanized ,Antifungal Agents ,Antineoplastic Combined Chemotherapy Protocols ,Bevacizumab ,Bone Neoplasms ,Chemotherapy ,Adjuvant ,Disease Progression ,Docetaxel ,Drug Therapy ,Combination ,Follow-Up Studies ,Humans ,International Agencies ,Ketoconazole ,Liver Neoplasms ,Lung Neoplasms ,Lymphatic Metastasis ,Male ,Middle Aged ,Neoplasm Staging ,Orchiectomy ,Prednisone ,Prognosis ,Prostatic Neoplasms ,Retrospective Studies ,Survival Rate ,Taxoids ,prostatic neoplasms ,chemotherapy ,ketoconazole ,steroid 17-alpha-hydroxylase ,androgen antagonists ,Alliance for Clinical Trials in Oncology ,Oncology and Carcinogenesis ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
BackgroundPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel-based chemotherapy, offered the opportunity to evaluate effect of prior ketoconazole, an earlier generation ASI, on clinical outcomes after docetaxel.MethodsIn CALGB trial 90401, 1050 men with chemotherapy-naive mCRPC were randomized to receive treatment with docetaxel and prednisone that included either bevacizumab or placebo. In total, 1005 men (96%) had data available regarding prior ketoconazole therapy. The observed effects of prior ketoconazole on overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) decline, and the objective response rate (ORR) were assessed using proportional hazards and Poisson regression methods adjusted for validated prognostic factors and treatment arm.ResultsBaseline characteristics between patients who did (N=277) and did not (N=728) receive prior ketoconazole therapy were similar. There were no statistically significant differences between patients who did and those who did not receive prior ketoconazole therapy with respect to OS (median OS, 21.1 months vs 22.3 months, respectively; stratified log-rank P=.635), PFS (median PFS, 8.1 months vs 8.6 months, respectively; stratified log-rank P=.342), the proportion achieving a decline ≥ 50% in PSA (61% vs 66%, respectively; relative risk, 1.09; adjusted P=.129), or ORR (39% vs 43%, respectively; relative risk, 1.11; adjusted P=.366).ConclusionsAs measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.
- Published
- 2013
14. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
- Author
-
Sumiyoshi, Takayuki, Wang, Xiaofei, Warner, Evan W, Sboner, Andrea, Annala, Matti, Sigouros, Michael, Beja, Kevin, Mizuno, Kei, Ku, Shengyu, Fazli, Ladan, Eastham, James, Taplin, Mary-Ellen, Simko, Jeffrey, Halabi, Susan, Morris, Michael J, Gleave, Martin E, Wyatt, Alexander W, and Beltran, Himisha
- Subjects
PROSTATE cancer ,GENE expression ,NEOADJUVANT chemotherapy ,RADICAL prostatectomy ,ANDROGEN deprivation therapy ,DNA sequencing - Abstract
Background The phase 3 CALGB 90203 (Alliance) trial evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. We dissected the molecular features of post-treated tumors with long-term clinical outcomes to explore mechanisms of response and resistance to chemohormonal therapy. Methods We evaluated 471 radical prostatectomy tumors, including 294 samples from 166 patients treated with 6 cycles of docetaxel plus androgen deprivation therapy before radical prostatectomy and 177 samples from 97 patients in the control arm (radical prostatectomy alone). Targeted DNA sequencing and RNA expression of tumor foci and adjacent noncancer regions were analyzed in conjunction with pathologic changes and clinical outcomes. Results Tumor fraction estimated from DNA sequencing was significantly lower in post-treated tumor tissues after chemohormonal therapy compared with controls. Higher tumor fraction after chemohormonal therapy was associated with aggressive pathologic features and poor outcomes, including prostate-specific antigen–progression-free survival. SPOP alterations were infrequently detected after chemohormonal therapy, while TP53 alterations were enriched and associated with shorter overall survival. Residual tumor fraction after chemohormonal therapy was linked to higher expression of androgen receptor–regulated genes, cell cycle genes, and neuroendocrine genes, suggesting persistent populations of active prostate cancer cells. Supervised clustering of post–treated high-tumor-fraction tissues identified a group of patients with elevated cell cycle–related gene expression and poor clinical outcomes. Conclusions Distinct recurrent prostate cancer genomic and transcriptomic features are observed after exposure to docetaxel and androgen deprivation therapy. Tumor fraction assessed by DNA sequencing quantifies pathologic response and could be a useful trial endpoint or prognostic biomarker. TP53 alterations and high cell cycle transcriptomic activity are linked to aggressive residual disease, despite potent chemohormonal therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1 / 2 Mutation: Results From the TAPUR Study.
- Author
-
Yang, Eddy S., Halabi, Susan, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Pisick, Evan, Dib, Elie, Burgess, Earle F., Zakem, Michael, Rohatgi, Nitin, Bilen, Mehmet A., O'Lone, Raegan, Grantham, Gina N., and Schilsky, Richard L.
- Subjects
- *
PROSTATE cancer patients , *PROSTATE cancer , *BRCA genes , *OLAPARIB , *CANCER patients , *PROGRESSION-free survival - Abstract
PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1 / 2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1 / 2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1 / 2 -mutated prostate cancer. Olaparib showed a positive signal of activity in real-world patients w/prostate cancer w/BRCA1 or BRCA2 mutations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer : Recommendations for Advancing Precision Medicine
- Author
-
Jasu, Juho, Tolonen, Teemu, Antonarakis, Emmanuel S., Beltran, Himisha, Halabi, Susan, Eisenberger, Mario A., Carducci, Michael A., Loriot, Yohann, Van der Eecken, Kim, Lolkema, Martijn, Ryan, Charles J., Taavitsainen, Sinja, Gillessen, Silke, Högnäs, Gunilla, Talvitie, Timo, Taylor, Robert J., Koskenalho, Antti, Ost, Piet, Murtola, Teemu J., Rinta-Kiikka, Irina, Tammela, Teuvo, Auvinen, Anssi, Kujala, Paula, Smith, Thomas J., Kellokumpu-Lehtinen, Pirkko Liisa, Isaacs, William B., Nykter, Matti, Kesseli, Juha, Bova, G. Steven, Tampere University, Department of Pathology, TAYS Cancer Centre, Clinical Medicine, BioMediTech, Tampere University Hospital Catchment Area, Department of Surgery, Department of Radiology, Health Sciences, and Medical Oncology
- Subjects
Complications ,Text mining ,Urology ,3122 Cancers ,Metastasis ,CONSENSUS CONFERENCE ,SDG 3 - Good Health and Well-being ,EVOLUTIONARY HISTORY ,Medicine and Health Sciences ,Electronic medical records ,RC254-282 ,TREATMENT RESPONSE ,AMERICAN-SOCIETY ,Outcome ,Prostate cancer ,Prostate Cancer ,Precision medicine ,RADICAL PROSTATECTOMY ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,NATURAL-HISTORY ,3126 Surgery, anesthesiology, intensive care, radiology ,Diseases of the genitourinary system. Urology ,CIRCULATING TUMOR-CELLS ,PROGNOSTIC MODEL ,3141 Health care science ,Phenotyping ,ANDROGEN DEPRIVATION THERAPY ,SURVIVAL ,RC870-923 ,Autopsy ,3111 Biomedicine - Abstract
Background Systematic identification of data essential for outcome prediction in metastatic prostate cancer (mPC) would accelerate development of precision oncology. Objective To identify novel phenotypes and features associated with mPC outcome, and to identify biomarker and data requirements to be tested in future precision oncology trials. Design, setting, and participants We analyzed deep longitudinal clinical, neuroendocrine expression, and autopsy data of 33 men who died from mPC between 1995 and 2004 (PELICAN33), and related findings to mPC biomarkers reported in the literature. Intervention Thirty-three men prospectively consented to participate in an integrated clinical-molecular rapid autopsy study of mPC. Outcome measurements and statistical analysis Data exploration with correction for multiple testing and survival analysis from the time of diagnosis to time to death and time to first occurrence of severe pain as outcomes were carried out. The effect of seven complications on the modeled probability of dying within 2 yr after presenting with the complication was evaluated using logistic regression. Results and limitations Feature exploration revealed novel phenotypes related to mPC outcome. Four complications (pleural effusion, severe anemia, severe or controlled pain, and bone fracture) predict the likelihood of death within 2 yr. Men with Gleason grade group 5 cancers developed severe pain sooner than those with lower-grade tumors. Surprisingly, neuroendocrine (NE) differentiation was frequently observed in the setting of high serum prostate-specific antigen (PSA) levels (≥30 ng/ml). In 4/33 patients, no controlled (requiring analgesics) or severe pain was detected, and strikingly, 14/15 metastatic sites studied in these men did not express NE markers, suggesting an inverse relationship between NE differentiation and pain in mPC. Intracranial subdural metastasis is common (36%) and is usually clinically undetected. Categorization of “skeletal-related events” complications used in recent studies likely obscures the understanding of spinal cord compression and fracture. Early death from prostate cancer was identified in a subgroup of men with a low longitudinal PSA bandwidth. Cachexia is common (body mass index, Take Home Message To better understand variation in metastatic prostate cancer behavior, we assembled and analyzed longitudinal clinical and autopsy records in 33 men. We identified novel outcomes, phenotypes, and aspects of disease burden to be tested and refined in future trials.
- Published
- 2021
17. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- Author
-
Gulley, James L., Arlen, Philip M., Madan, Ravi A., Tsang, Kwong-Yok, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., and Schlom, Jeffrey
- Published
- 2010
- Full Text
- View/download PDF
18. A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection.
- Author
-
Dutta, Sandipan and Halabi, Susan
- Subjects
- *
DETECTION limit , *OVERALL survival , *BIOMARKERS , *PROSTATE cancer , *PROGNOSIS , *TOBITS - Abstract
Before biomarkers can be used in clinical trials or patients' management, the laboratory assays that measure their levels have to go through development and analytical validation. One of the most critical performance metrics for validation of any assay is related to the minimum amount of values that can be detected and any value below this limit is referred to as below the limit of detection (LOD). Most of the existing approaches that model such biomarkers, restricted by LOD, are parametric in nature. These parametric models, however, heavily depend on the distributional assumptions, and can result in loss of precision under the model or the distributional misspecifications. Using an example from a prostate cancer clinical trial, we show how a critical relationship between serum androgen biomarker and a prognostic factor of overall survival is completely missed by the widely used parametric Tobit model. Motivated by this example, we implement a semiparametric approach, through a pseudo‐value technique, that effectively captures the important relationship between the LOD restricted serum androgen and the prognostic factor. Our simulations show that the pseudo‐value based semiparametric model outperforms a commonly used parametric model for modeling below LOD biomarkers by having lower mean square errors of estimation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer.
- Author
-
George, Daniel J., Halabi, Susan, Heath, Elisabeth I., Sartor, A. Oliver, Sonpavde, Guru P., Das, Devika, Bitting, Rhonda L., Berry, William, Healy, Patrick, Anand, Monika, Winters, Carol, Riggan, Colleen, Kephart, Julie, Wilder, Rhonda, Shobe, Kellie, Rasmussen, Julia, Milowsky, Matthew I., Fleming, Mark T., Bearden, James, and Goodman, Michael
- Subjects
- *
ABIRATERONE acetate , *WHITE men , *BLACK men , *CASTRATION-resistant prostate cancer , *PROSTATE cancer , *METASTATIC breast cancer - Abstract
Background: Retrospective analyses of randomized trials suggest that Black men with metastatic castration‐resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednisone to explore outcomes by race. Methods: This race‐stratified, multicenter study estimated radiographic progression‐free survival (rPFS) in Black and White men with mCRPC. Secondary end points included prostate‐specific antigen (PSA) kinetics, overall survival (OS), and safety. Exploratory analysis included genome‐wide genotyping to identify single nucleotide polymorphisms associated with progression in a model incorporating genetic ancestry. One hundred patients self‐identified as White (n = 50) or Black (n = 50) were enrolled. Eligibility criteria were modified to facilitate the enrollment of individual Black patients. Results: The median rPFS for Black and White patients was 16.6 and 16.8 months, respectively; their times to PSA progression (TTP) were 16.6 and 11.5 months, respectively; and their OS was 35.9 and 35.7 months, respectively. Estimated rates of PSA decline by ≥50% in Black and White patients were 74% and 66%, respectively; and PSA declines to <0.2 ng/mL were 26% and 10%, respectively. Rates of grade 3 and 4 hypertension, hypokalemia, and hyperglycemia were higher in Black men. Conclusions: Multicenter prospective studies by race are feasible in men with mCRPC but require less restrictive eligibility. Despite higher comorbidity rates, Black patients demonstrated rPFS and OS similar to those of White patients and trended toward greater TTP and PSA declines, consistent with retrospective reports. Importantly, Black men may have higher side‐effect rates than White men. This exploratory genome‐wide analysis of TTP identified a possible candidate marker of ancestry‐dependent treatment outcomes. This is the first prospective, race‐stratified study in advanced prostate cancer demonstrating important trends in outcomes previously only observed in retrospective reports. These results demonstrate the feasibility of this approach in a multicenter setting and establish important preliminary data with regard to differences in toxicity profiles and predictive biomarkers by race. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study
- Author
-
Levine, Ellis G., Halabi, Susan, Roberts, John D., Kaplan, Ellen B., Rago, Randall, Atkins, James N., and Vogelzang, Nicholas J.
- Subjects
Prostate cancer ,Mitoxantrone hydrochloride -- Dosage and administration ,Health - Published
- 2002
21. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B Study 9181
- Author
-
Dawson, Nancy A., Conaway, Mark, Halabi, Susan, Winer, Eric P., Small, Eric J., Lake, Diana, and Vogelzang, Nicholas J.
- Subjects
Prostate cancer ,Megestrol acetate -- Dosage and administration ,Health - Published
- 2000
22. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
- Author
-
Halabi, Susan, Dutta, Sandipan, Tangen, Catherine M, Rosenthal, Mark, Petrylak, Daniel P, Thompson, Ian M, Chi, Kim N, Bono, Johann S De, Araujo, John C, Logothetis, Christopher, Eisenberger, Mario A, Quinn, David I, Fizazi, Karim, Morris, Michael J, Higano, Celestia S, Tannock, Ian F, Small, Eric J, and Kelly, William Kevin
- Subjects
PROSTATE cancer treatment ,CASTRATION-resistant prostate cancer ,DOCETAXEL ,PROSTATE cancer ,ASIANS ,WHITE men - Abstract
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% CI = 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
- Author
-
Armstrong, Andrew J., Gupta, Santosh, Healy, Patrick, Kemeny, Gabor, Leith, Beth, Zalutsky, Michael R., Spritzer, Charles, Davies, Catrin, Rothwell, Colin, Ware, Kathryn, Somarelli, Jason A., Wood, Kris, Ribar, Thomas, Giannakakou, Paraskevi, Zhang, Jiaren, Gerber, Drew, Anand, Monika, Foo, Wen-Chi, Halabi, Susan, and Gregory, Simon G.
- Subjects
CASTRATION-resistant prostate cancer ,ALKALINE phosphatase ,EXOCRINE glands ,THERAPEUTICS ,BONE cancer ,BONES - Abstract
Background: Radium-223 is a targeted alpha-particle therapy that improves survival in men with metastatic castration resistant prostate cancer (mCRPC), particularly in men with elevated serum levels of bone alkaline phosphatase (B-ALP). We hypothesized that osteomimicry, a form of epithelial plasticity leading to an osteoblastic phenotype, may contribute to intralesional deposition of radium-223 and subsequent irradiation of the tumor microenvironment. Methods: We conducted a pharmacodynamic study (NCT02204943) of radium-223 in men with bone mCRPC. Prior to and three and six months after radium-223 treatment initiation, we collected CTCs and metastatic biopsies for phenotypic characterization and CTC genomic analysis. The primary objective was to describe the impact of radium-223 on the prevalence of CTC B-ALP over time. We measured radium-223 decay products in tumor and surrounding normal bone during treatment. We validated genomic findings in a separate independent study of men with bone metastatic mCRPC (n = 45) and publicly accessible data of metastatic CRPC tissues. Results: We enrolled 20 men with symptomatic bone predominant mCRPC and treated with radium-223. We observed greater radium-223 radioactivity levels in metastatic bone tumor containing biopsies compared with adjacent normal bone. We found evidence of persistent Cellsearch CTCs and B-ALP (+) CTCs in the majority of men over time during radium-223 therapy despite serum B-ALP normalization. We identified genomic gains in osteoblast mimicry genes including gains of ALPL, osteopontin, SPARC, OB-cadherin and loss of RUNX2, and validated genomic alterations or increased expression at the DNA and RNA level in an independent cohort of 45 men with bone-metastatic CRPC and in 150 metastatic biopsies from men with mCRPC. Conclusions: Osteomimicry may contribute in part to the uptake of radium-223 within bone metastases and may thereby enhance the therapeutic benefit of this bone targeting radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)
- Author
-
Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F, Millard, Frederick, Stadler, Walter M, Morris, Michael J, Kantoff, Philip, Monk, J Paul, Carducci, Michael, Small, Eric J, and Alliance for Clinical Trials in Oncology
- Subjects
Male ,Urologic Diseases ,Lung Neoplasms ,Antifungal Agents ,ketoconazole ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,Bone Neoplasms ,Docetaxel ,chemotherapy ,Antibodies ,prostatic neoplasms ,steroid 17-alpha-hydroxylase ,Drug Therapy ,Clinical Research ,Antineoplastic Combined Chemotherapy Protocols ,Monoclonal ,Humans ,Oncology & Carcinogenesis ,Humanized ,Adjuvant ,androgen antagonists ,Neoplasm Staging ,Retrospective Studies ,Aged ,Cancer ,Alliance for Clinical Trials in Oncology ,Prostate Cancer ,Liver Neoplasms ,International Agencies ,Evaluation of treatments and therapeutic interventions ,Middle Aged ,Prognosis ,Survival Rate ,Bevacizumab ,Lymphatic Metastasis ,6.1 Pharmaceuticals ,Combination ,Disease Progression ,Public Health and Health Services ,Prednisone ,Taxoids ,Orchiectomy ,Follow-Up Studies - Abstract
BackgroundPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel-based chemotherapy, offered the opportunity to evaluate effect of prior ketoconazole, an earlier generation ASI, on clinical outcomes after docetaxel.MethodsIn CALGB trial 90401, 1050 men with chemotherapy-naive mCRPC were randomized to receive treatment with docetaxel and prednisone that included either bevacizumab or placebo. In total, 1005 men (96%) had data available regarding prior ketoconazole therapy. The observed effects of prior ketoconazole on overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) decline, and the objective response rate (ORR) were assessed using proportional hazards and Poisson regression methods adjusted for validated prognostic factors and treatment arm.ResultsBaseline characteristics between patients who did (N=277) and did not (N=728) receive prior ketoconazole therapy were similar. There were no statistically significant differences between patients who did and those who did not receive prior ketoconazole therapy with respect to OS (median OS, 21.1 months vs 22.3 months, respectively; stratified log-rank P=.635), PFS (median PFS, 8.1 months vs 8.6 months, respectively; stratified log-rank P=.342), the proportion achieving a decline ≥ 50% in PSA (61% vs 66%, respectively; relative risk, 1.09; adjusted P=.129), or ORR (39% vs 43%, respectively; relative risk, 1.11; adjusted P=.366).ConclusionsAs measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.
- Published
- 2013
25. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
- Author
-
Armstrong, Andrew J., Halabi, Susan, Healy, Patrick, Alumkal, Joshi J., Winters, Carolyn, Kephart, Julie, Bitting, Rhonda L., Hobbs, Carey, Soleau, Colleen F., Beer, Tomasz M., Slottke, Rachel, Mundy, Kelly, Yu, Evan Y., and George, Daniel J.
- Subjects
- *
AFFECTIVE disorders , *ANOREXIA nervosa , *ANTIANDROGENS , *ANTINEOPLASTIC agents , *COGNITION disorders , *CONFIDENCE intervals , *SEIZURES (Medicine) , *DIARRHEA , *EXANTHEMA , *FATIGUE (Physiology) , *HYPERGLYCEMIA , *MEDICAL cooperation , *METASTASIS , *MULTIPLE organ failure , *NAUSEA , *PROSTATE tumors , *RESEARCH , *RESPIRATORY infections , *SPASMS , *URINARY organs , *WEIGHT loss , *DOCETAXEL , *PROSTATE-specific antigen , *PROTEIN kinase inhibitors , *DESCRIPTIVE statistics ,CENTRAL nervous system tumors - Abstract
Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. Methods This was a multisite single arm phase II trial of buparlisib 100 mg ± enzalutamide daily in men with mCRPC whose disease progressed on or who were not candidates for docetaxel. The primary end-point was the rate of radiographic/clinical progression-free survival (PFS) at 6 months. Results Thirty men were accrued: 67% post-docetaxel; median prostate specific antigen (PSA) was 70 ng/dl, 83% had ≥4 prior therapies for mCRPC; 43% received concurrent enzalutamide. The final 6 month PFS rate was estimated to be 10% (95% confidence interval 2.5–23.6%). Median PFS was 1.9 months and was 3.5 months with concurrent enzalutamide. Median overall survival was 10.6 months. Concurrent enzalutamide led to a five-fold reduction in buparlisib concentrations. PSA declines were observed in 23%; no patients achieved a ≥50% decline, and no radiographic responses were observed. Severe adverse events occurred in four men including respiratory infection and multi-organ failure, urinary tract obstruction, confusion and one seizure in the setting of a new central nervous system (CNS) metastasis. Grade III adverse events were seen in 43% of patients; common toxicities included grade I–II weight loss, diarrhoea, nausea, fatigue, anorexia, rash, hyperglycemia and anxiety/mood disorders. Conclusions Buparlisib did not demonstrate significant activity in men with mCRPC, suggesting that PI3K inhibition is not sufficient to reverse resistant mCRPC progression. Future studies of PI3K pathway inhibitors with concurrent enzalutamide should develop optimal dosing and focus on selected patients more likely to benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy.
- Author
-
Monk, J. Paul, Halabi, Susan, Picus, Joel, Hussain, Arif, Philips, George, Kaplan, Ellen, Ahles, Tim, Gu, Lin, Vogelzang, Nicholas, Kelly, William K., and Small, Eric J.
- Subjects
- *
DRUG efficacy , *ANTIANDROGENS , *PROSTATE cancer treatment , *REDUCTASE inhibitors , *CLINICAL trials , *CANCER patients , *PROSTATE-specific antigen - Abstract
BACKGROUND: The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5-alpha reductase inhibitor and an antiandrogen may allow control of the prostate-specific antigen (PSA). Because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression. METHODS: All patients had undergone previous definitive local therapy and had evidence of a rising PSA >1ng/mL, with no evidence of recurrent disease. Patients received both finasteride, 5 mg orally per day, and flutamide, 250 mg orally 3× a day. Patients were followed for a PSA response and quality of life assessment. RESULTS: Ninety-nine of 101 accrued patients were eligible. A ≥80% PSA decline was seen in 96 (96%) patients. The median time to PSA progression was 85 months. With a median follow-up of 10 years, the median survival time had not been reached, and the 5-year overall survival rate was 87%. Toxicity was mild, with 18 patients stopping for toxicity; 15 had diarrhea, 4 had gynecomastia, and 3 had transaminase elevation. Baseline Functional Assessment of Cancer Therapy Prostate Module and Treatment Outcome Index scores decreased by 5 points each at 6 months after enrollment. CONCLUSIONS: The use of the finasteride/flutamide combination is feasible, and results in PSA declines of ≥80% in 96% of patients with serologic progression after definitive local therapy. There were no unexpected toxicities, and the change in quality of life was mild. Further evaluation of this or a similar regimen in a controlled clinical trial is warranted. Cancer 2012. © 2011 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
27. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer.
- Author
-
Picus, Joel, Halabi, Susan, Kelly, W. Kevin, Vogelzang, Nicholas J., Whang, Young E., Kaplan, Ellen B., Stadler, Walter M., and Small, Eric J.
- Subjects
- *
DOCETAXEL , *BEVACIZUMAB , *PROSTATE cancer , *DISEASE progression , *VASCULAR endothelial growth factors , *DISEASES in men - Abstract
BACKGROUND: The use of docetaxel prolongs survival for patients with castrate-resistant prostate cancer (CRPC). Inhibition of vascular endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in patients with CRPC. METHODS: This cooperative group trial enrolled men with CRPC. Patients received oral estramustine 280 mg 3 times daily on Days 1 through 5 of every cycle plus 70 mg/m² docetaxel and 15 mg/kg bevacizumab on Day 2 every 3 weeks. Prostate-specific antigen (PSA) values were monitored every cycle, and imaging studies were obtained every 3 cycles. The primary endpoint was progression-free survival (PFS), and the secondary objectives were safety, PSA decline, measurable disease response, and overall survival. RESULTS: Seventy-nine patients were enrolled; and 77 patients received a median of 8 cycles and were evaluable. A 50% PSA decline was observed in 58 patients (75%). Twenty-three of 39 patients with measurable disease had a partial response (59%). The median PFS was 8 months, and the overall median survival was 24 months. Neutropenia without fever (69%), fatigue (25%), and thrombosis/emboli (9%) were the most common severe toxicities. Twenty-four of 77 patients were removed from protocol treatment because of disease progression, 35 of 77 patients were removed because of a physician or patient decision, and 15 patients were removed secondary to toxicity. CONCLUSIONS: The combination of docetaxel, estramustine, and bevacizumab was tolerable but complicated by toxicity. Although the endpoint of PFS did not meet the desired level, encouraging antitumor activity and overall survival were observed. Further phase 3 evaluation of the role of bevacizumab in CRPC is ongoing. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
28. Multicenter Phase 2 Study of Neoadjuvant Paclitaxel, Estramustine Phosphate, and Carboplatin Plus Androgen Deprivation Before Radiation Therapy in Patients With Unfavorable-Risk Localized Prostate Cancer: Results of Cancer and Leukemia Group B 99811.
- Author
-
Kelly, William Kevin, Halabi, Susan, Elfiky, Aymen, San-San Ou, Bogart, Jeff, Zelefsky, Michael, and Small, Eric
- Subjects
- *
RADIOTHERAPY , *PACLITAXEL , *PROSTATE cancer , *PROSTATE cancer treatment , *CANCER patients , *CANCER education - Abstract
The article presents a study which evaluates the safety and feasibility of radiotherapy after paclitaxel, estramustine phosphate and carboplatin (TEC) plus androgen therapy in previously treated prostate cancer patients. It mentions that patients with localized high-risk prostate cancer were treated with four cycles of paclitaxel in a period of 16 weeks. It affirms that the authors concluded that neoadjuvant chemohormonal therapy with TEC followed by high-dose radiation therapy is safe.
- Published
- 2008
- Full Text
- View/download PDF
29. Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study
- Author
-
D'Amico, Anthony V., Halabi, Susan, Tempany, Clare, Titelbaum, David, Philips, George K., Loffredo, Marian, McMahon, Elizabeth, Sanford, Ben, Vogelzang, Nicholas J., and Small, Eric J.
- Subjects
- *
RADIOTHERAPY , *MALE reproductive organ cancer , *MAGNETIC resonance imaging , *TUMORS - Abstract
Purpose: We prospectively determined whether the change in tumor volume (TV) during 2 months of neoadjuvant androgen suppression therapy (nAST) measured using conventional 1.5 Tesla endorectal magnetic resonance imaging (eMRI) was associated with the risk of recurrence after radiation (RT) and 6 months of AST. Patients and Methods: Between 1997 and 2001, 180 men with clinical stage T1c-T3cN0M0 adenocarcinoma of the prostate were registered. Fifteen were found to be ineligible and the institutional MR radiologist could not assess the TV in 32, leaving 133 for analysis. Multivariable Cox regression analysis was used to assess whether a significant association existed between eMRI-defined TV progression during nAST and time to recurrence adjusting for prostate-specific antigen (PSA) level, Gleason score (8 to 10 or 7 vs. 6 or less) and stage (T3 vs. T1-2). Results: After a median follow up of 6.7 years and adjusting for known prognostic factors, there was a significant increase in the risk of PSA failure (HR, 2.3 [95% CI, 1.1–4.5; p = 0.025) in men with eMRI-defined TV progression during nAST. Specifically, adjusted estimates of PSA failure were significantly higher (p = 0.032) in men with, compared with men without, eMRI-defined TV progression reaching 38% vs. 19%, respectively, by 5 years. Conclusion: Eradicating intraprostatic hormone refractory prostate cancer (HRPC) by maximizing local control and randomized trials assessing whether survival is improved when agents active against HRPC are combined with maximal local therapy are needed in men who progress based on eMRI during nAST. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
30. Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer
- Author
-
Halabi, Susan
- Subjects
- *
CLINICAL trials , *CLINICAL medicine research , *MEDICAL research , *MEDICAL experimentation on humans - Abstract
Abstract: This article reviews the basic principles involved in the design, conduct, and analysis of Phase III treatment trials in prostate cancer. It begins with a brief review of Phase III trials, and subsequently describes the process of hypothesis testing and the types of errors involved in the process of statistical inference. Next, it presents a general discussion of design considerations, including choice of endpoints, patient selection and eligibility criteria, randomization and stratification, methods to determine the required number patients, standard procedures to monitor a study, and finally how to analyze the results from randomized clinical trials. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
31. Inverse Correlation Between Body Mass Index and Clinical Outcomes in Men With Advanced Castration--Recurrent Prostate Cancer.
- Author
-
Halabi, Susan, San-San Ou, Vogelzang, Nicholas J., and Small, Eric J.
- Subjects
- *
BODY mass index , *PROSTATE cancer , *OBESITY , *CASTRATION , *RENAL cell carcinoma , *CANCER-related mortality - Abstract
The article focuses on a study that aims to evaluate the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC). It cites the association between obesity and the risk of certain malignancies such as colon cancer and renal cell carcinoma. It concludes that patients with metastatic CRPC, obesity appears to have a protective effect against overall mortality and prostate cancer-specific mortality.
- Published
- 2007
- Full Text
- View/download PDF
32. The Impact of Prior Radical Prostatectomy in Men With Metastatic Castration Recurrent Prostate Cancer: A Pooled Analysis of 9 Cancer and Leukemia Group B Trials.
- Author
-
Halabi, Susan, Vogelzang, Nicholas J., Ou, San-San, and Small, Eric J.
- Subjects
PROSTATECTOMY ,PROSTATE surgery ,CASTRATION ,PROSTATE cancer ,CANCER treatment ,CANCER patients - Abstract
Purpose: A prior report suggested that radical prostatectomy may confer a survival advantage to patients with metastatic castration recurrent prostate cancer. Therefore, a pooled analysis of 9 trials performed by Cancer and Leukemia Group B was done to determine if men with metastatic castration recurrent prostate cancer who underwent prior prostatectomy had improved clinical outcomes, such as overall, prostate specific, progression-free and PSA progression-free survival, than men who did not undergo prior prostatectomy. Materials and Methods: Data from 9 multi-institutional trials performed by Cancer and Leukemia Group B were combined. Eligible patients had progressive prostate cancer during androgen deprivation therapy, Eastern Cooperative Oncology Group performance status 0–2, and adequate hematological, renal and hepatic functions. The proportional hazards model was used to assess the prognostic importance of radical prostatectomy for predicting clinical outcomes. Results: Of 1,238 men 310 (25%) underwent prostatectomy. Median survival was 14.7 (95% CI 12.9–16.7) and 14.5 months (95% CI 13.5–15.7) in men who did and did not undergo prostatectomy, respectively. The HR for death was 1.03 (95% CI 0.90–1.19, p = 0.65) in men with vs without prostatectomy. Conclusions: Prior prostatectomy in men with metastatic castration recurrent prostate cancer who were subsequently enrolled on clinical trials for cancer treatment had similar survival compared to men who did not undergo prior prostatectomy. These data do not support another report suggesting that prior prostatectomy confers a subsequent survival advantage in men with castration recurrent prostate cancer. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
33. Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) Studies.
- Author
-
Halabi, Susan, Vogelzang, Nicholas J., Ou, San-San, Kelly, Wm. Kevin, and Small, Eric J.
- Subjects
PROSTATE cancer ,CANCER patients ,MEDICAL care ,LEUKEMIA - Abstract
Purpose: We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer. Materials and Methods: Data from 8 multi-institutional trials performed by Cancer and Leukemia Group B were combined. Eligible patients had progressive adenocarcinoma of the prostate after androgen ablation, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate hematological, renal and hepatic function. The proportional hazards model stratified by study was used to assess the prognostic importance of age for predicting clinical outcomes. Results: Of 1,194 men 132 (11%) were 50 to 60 years old and 120 (10%) were 80 to 89 years old. Median survival was 12.2 months (95% CI 10.6 to 13.8) in men 50 to 59 years old, 15.9 months (95% CI 14.2 to 17.6) in men 60 to 69 years old, 15.6 months (95% CI 13.8 to 16.9) in men 70 to 79 years old and 8.9 months (95% CI 6.6 to 12.1) in men 80 to 89 years old. Compared to 70 to 79-year-old men the HR for death in octogenarians was 1.3 (95% CI 1.0 to 1.6, p = 0.015). Furthermore, the HR for prostate cancer death in octogenarians was 1.3 (95% CI 1.1 to 1.7, p = 0.010) and in 50 to 59-year-old men it was 1.3 (95% CI 1.0 to 1.6, p = 0.042) compared to men 70 to 79 years old. Black men were at lower risk for death than white men (HR 0.77, 95 CI% 0.65 to 0.92, p = 0.004). Conclusions: Octogenarians and white men are at increased risk for death compared to other men with hormone refractory prostate cancer. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
34. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901
- Author
-
Amin, Asim, Halabi, Susan, Gelmann, Edward P., Stadler, Walter, Vogelzang, Nicholas, and Small, Eric
- Subjects
- *
CANCER treatment , *DRUG therapy , *PROSTATE cancer , *CANCER hormone therapy - Abstract
Background: Institution of early hormone therapy in the PSA era coupled with demonstration of clinical benefit with chemotherapy in hormone refractory prostate cancer (HRPC) and acceptance of PSA decline as a surrogate for response has resulted in introduction of chemotherapy earlier in the natural history of disease. There now exists a need to identify, effective agents for second line chemotherapy. 9-Nitrocamptothecin (9-NC) a novel, oral camptothecin analogue was tested as second line chemotherapy for patients with progressive hormone refractory prostate cancer.Patients and methods: Eligible patients had metastatic hormone refractory prostate cancer with performance status (0–1) following progression on at least 1 prior cytotoxic chemotherapy. 9-NC was administered orally at the dose of 1.5 mg/m2/d for 5 days each week for 3 weeks, followed by rest for 1 week. Response was evaluated after 2 cycles according to the guidelines set forth for Phase II trials in HRPC by the PSA working group.Results: Thirty-five patients were recruited to the study within a period of 6 months; 33 were evaluable for analysis. No patients had a >50% decline in PSA levels. Two out of 8 (25%) patients with measurable disease and 5/25 (20%) patients with nonmeasurable disease showed stable disease. The median time to disease and PSA progression was 2 months [95% confidence interval (CI), 0.9–2.8]. The median overall survival was 10 months (95% CI = 5–12). Seven patients are alive after a median follow-up of 23 months.Conclusions: 9-Nitrocamptothecin failed to elicit clinical or PSA responses. Further study in pretreated HRPC patients is not warranted. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
35. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
- Author
-
Koontz, Bridget F., Hoffman, Karen E., Halabi, Susan, Healy, Patrick, Anand, Monika, George, Daniel J., Harrison, Michael R., Zhang, Tian, Berry, William R., Corn, Paul G., Lee, W. Robert, and Armstrong, Andrew J.
- Subjects
- *
ABIRATERONE acetate , *PROSTATE cancer , *RADIOTHERAPY , *ANDROGENS , *PROSTATE-specific antigen - Abstract
Purpose: Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiation therapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of more potent but shorter-term androgen inhibition in men with intermediate- or high-risk localized PC would synergize with definitive RT to provide short-term testosterone recovery and improve disease control.Methods and Materials: This prospective phase 2 single-arm trial enrolled men with low-volume unfavorable intermediate or high-risk localized PC. Treatment included 6 months of ADT concurrent with abiraterone acetate plus prednisone (AAP) once daily and RT to prostate and seminal vesicles. The primary endpoint was the proportion of men with an undetectable prostate-specific antigen (PSA) at 12-months; secondary objectives included biochemical progression-free survival (PFS), testosterone recovery, toxicity, and sexual and hormonal quality of life.Results: We enrolled 37 men between January 2014 and August 2016, 45% of whom were high risk. All patients had T1-2 disease and PSA < 20 ng/mL. Median follow-up is 37 months (95% confidence interval [CI], 35.7-39.1). Treatment noted 32% grade 3 toxicities related to AAP, predominantly hypertension, with no toxicities ≥G4. The rate of undetectable PSA at 12 months was 55% (95% CI, 36%-72%). With 46 months of median follow-up, 2 of 37 patients developed PSA progression (36-month PFS = 96%; 95% CI, 76%-99%), and 81% of patients recovered testosterone with a median time to recovery of 9.2 months. Hormonal or sexual function declined at 6 months with subsequent improvement by 24 months.Conclusions: The combination of RT and 6 months of ADT and AAP demonstrated acceptable toxicity and a high rate of testosterone recovery with restoration of quality of life and excellent disease control in men with low-volume, intermediate- or high-risk localized prostate cancer. Prospective comparative studies are justified. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
36. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
- Author
-
Taplin, Mary-Ellen, George, Daniel J., Halabi, Susan, Sanford, Ben, Febbo, Philip G., Hennessy, Kristen T., Mihos, Christos G., Vogelzang, Nicholas J., Small, Eric J., and Kantoff, Philip W.
- Subjects
- *
CHROMOGRANINS , *PROSTATE cancer , *LIPOPROTEINS , *LEUKEMIA - Abstract
Abstract: Objectives: To test the hypothesis that chromogranin A (CgA) levels are prognostic in patients with metastatic hormone-refractory prostate cancer (HRPC). The extent of neuroendocrine differentiation in prostate cancer correlates with aggressive disease and with progression to HRPC. Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype. Methods: Pretreatment plasma was collected from 390 patients with metastatic HRPC enrolled in the Cancer and Leukemia Group B (CALGB) 9480 trial, a study of three different doses of suramin. Plasma CgA levels were determined in 321 samples in duplicate using a quantitative sandwich immunoassay. The proportional hazards model was used to assess the prognostic significance of CgA in predicting overall survival. Results: The median plasma CgA level was 12 U/L (interquartile range 7.7 to 19.3). In univariate analysis, plasma CgA correlated inversely with survival times, with a survival time of 17 months for low CgA (less than 12 U/L, 95% CI 14 to 19) compared with 11 months for high CgA (95% CI 8 to 14, P = 0.014) and at all exploratory cutpoints, including CgA of 9.5 U/L or less versus greater than 9.5 U/L, with survival of 19 months compared with 12 months (P = 0.0015). In multivariate models (adjusting for performance status, prostate-specific antigen, and lactate dehydrogenase), the plasma CgA levels remained predictive of overall survival. Conclusions: These results support the hypothesis that serum CgA levels correlate with outcome in patients with HRPC, although the clinical significance needs to be established in confirmatory studies before incorporation of CgA measurements in clinical practice. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
37. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.
- Author
-
Hofmann, Martin R., Hussain, Maha, Dehm, Scott M., Beltran, Himisha, Wyatt, Alexander W., Halabi, Susan, Sweeney, Christopher, Scher, Howard I., Ryan, Charles J., Feng, Felix Y., Attard, Gerhardt, Klein, Eric, Miyahira, Andrea K., Soule, Howard R., and Sharifi, Nima
- Subjects
- *
PROSTATE cancer , *ANDROGEN deprivation therapy , *BIOMARKERS - Abstract
Androgen deprivation therapy remains the backbone therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when used upfront along with androgen deprivation therapy. However, treatment selection for an individual patient remains a challenge. There is no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized here. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, with emphasis on charting a course for the generation, interrogation, and clinical implementation of biomarkers for treatment selection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
- Author
-
Gharzai, Laila A, Jiang, Ralph, Wallington, David, Jones, Gavin, Birer, Samuel, Jairath, Neil, Jaworski, Elizabeth M, McFarlane, Matthew R, Mahal, Brandon A, Nguyen, Paul L, Sandler, Howard, Morgan, Todd M, Reichert, Zachery R, Alumkal, Joshi J, Mehra, Rohit, Kishan, Amar U, Fizazi, Karim, Halabi, Susan, Schaeffer, Edward M, and Feng, Felix Y
- Subjects
- *
PROGRESSION-free survival , *PROSTATE cancer , *SAMPLE size (Statistics) , *PROSTATE tumors treatment , *RESEARCH , *META-analysis , *RESEARCH methodology , *CANCER relapse , *METASTASIS , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *RESEARCH funding , *COMBINED modality therapy , *PROSTATE tumors , *LONGITUDINAL method - Abstract
Background: The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials. We sought to comprehensively assess aggregate trial-level performance of commonly reported intermediate clinical endpoints across all randomised trials in localised prostate cancer.Methods: For this meta-analysis, we searched PubMed for all trials in localised or biochemically recurrent prostate cancer published between Jan 1, 1970, and Jan 15, 2020. Eligible trials had to be randomised, therapeutic, reporting overall survival and at least one intermediate clinical endpoint, and with a sample size of at least 70 participants. Trials of metastatic disease were excluded. Intermediate clinical endpoints included biochemical failure, local failure, distant metastases, biochemical failure-free survival, progression-free survival, and metastasis-free survival. Candidacy for surrogacy was assessed using the second condition of the meta-analytical approach (ie, correlation of the treatment effect of the intermediate clinical endpoint and overall survival), using R2 weighted by the inverse variance of the log intermediate clinical endpoint hazard ratio. The intermediate clinical endpoint was deemed to be a surrogate for overall survival if R2 was 0·7 or greater.Findings: 75 trials (53 631 patients) were included in our analysis. Median follow-up was 9·1 years (IQR 5·7-10·6). Biochemical failure (R2 0·38 [95% CI 0·11-0·64]), biochemical failure-free survival (R2 0·12 [0·0030-0·33]), biochemical failure and clinical failure (R2 0·28 [0·0045-0·65]), and local failure (R2 0·085 [0·00-0·37]) correlated poorly with overall survival. Progression-free survival (R2 0·46 [95% CI 0·22-0·67]) showed moderate correlation with overall survival, and metastasis-free survival (R2 0·78 [0·59-0·89]) correlated strongly.Interpretation: Intermediate clinical endpoints based on biochemical and local failure did not meet the second condition of the meta-analytical approach and are not surrogate endpoints for overall survival in localised prostate cancer. Our findings validate metastasis-free survival as the only identified surrogate endpoint for overall survival to date.Funding: Prostate Cancer Foundation and National Institutes of Health. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
39. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration–resistant prostate cancer.
- Author
-
Bitting, Rhonda L., Healy, Patrick, Halabi, Susan, George, Daniel J., Goodin, Michael, and Armstrong, Andrew J.
- Subjects
- *
PHENOTYPES , *PROSTATE cancer , *CASTRATION , *LACTATE dehydrogenase , *ALKALINE phosphatase - Abstract
Background The presence of ≥5 circulating tumor cells (CTCs) is prognostic for shorter survival in men with metastatic castration–resistant prostate cancer (mCRPC). However, some men have low CTCs despite widespread disease, suggesting heterogeneity in CTC phenotype or detection. The aim of this study was to evaluate the association of CTC enumeration with clinical disease characteristics and overall survival in men with mCRPC at our institution. Design CTCs were enumerated using the CellSearch method in a prospective correlative study in men with mCRPC starting a new systemic therapy. The primary objective was to determine the clinical phenotype of the subset of men with mCRPC who have a poor prognosis and low CTCs. Secondary end points included associations of CTCs with survival and known prognostic biomarkers, before therapy and at progression. Results At baseline, median CTC count was 16 cells and prostate-specific antigen (PSA) level was 178 ng/ml. At progression, median CTC count was 42, PSA level was 245 ng/ml, levels of lactate dehydrogenase and alkaline phosphatase rose, and level of hemoglobin dropped. The median overall survival for this heavily pretreated population was 11.2 months, and the multivariable hazard ratio for death of men with CTCs<5 vs.≥5 was 0.43 (95% CI: 0.24–0.77). Median progression-free survival was 4.4 months. CTC enumeration modestly correlated with lactate dehydrogenase and alkaline phosphatase levels but only weakly correlated with PSA and hemoglobin levels. We were unable to identify a consistent subgroup of poor prognosis men with a low number of CTCs. Conclusion CTC enumeration appears to be prognostic in men with mCRPC and describes a phenotype of hematogenous dissemination that cannot be predicted based on standard clinical and laboratory assessments. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
- Author
-
Armstrong, Andrew J., Tannock, Ian F., Wit, Ronald de, George, Daniel J., Eisenberger, Mario, and Halabi, Susan
- Subjects
- *
PROSTATE cancer risk factors , *PROSTATE-specific antigen , *DRUG therapy , *DOCETAXEL , *PREDNISONE , *ANTINEOPLASTIC agents , *CANCER in men - Abstract
Abstract: Aims of the study: There are no known predictive factors of response in men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). We investigated pre-treatment factors that predicted a ⩾30% PSA decline (30% PSAD) within 3 months of starting chemotherapy, and assessed performance of a risk group classification in predicting PSA declines and overall survival (OS) in men with mCRPC. Methods: In TAX327, 1006 men with mCRPC were randomized to receive docetaxel (D) in two schedules, or mitoxantrone (M), each with prednisone: 989 provided data on PSA decline within 3 months. Predictive factors for a 30% PSAD were identified using multivariable regression in D-treated men (n =656) and validated in M-treated men (n =333). Results: Four independent risk factors predicted 30% PSAD: pain, visceral metastases, anaemia and bone scan progression. Risk groups (good: 0–1 factors, intermediate: 2 factors and poor: 3–4 factors) were developed with median OS of 25.7, 18.7 and 12.8 months (p <0.0001); 30% PSAD in 78%, 66% and 58% of men (p <0.001); and measurable disease response in 19%, 9% and 5% of men (p =0.018), respectively. In the validation cohort, similar predictive ability was noted for 30% PSAD, tumour response and OS. PCWG2 subtypes were also predictive but resulted in unequal grouping. C-indices were 0.59 and 0.62 for 30% PSAD and OS in the validation dataset, respectively. Conclusions: Risk groups have been identified and validated that predict PSAD and OS in men with mCRPC and may facilitate evaluation of new systemic regimens warranting definitive testing in comparison with docetaxel and prednisone. Prospective validation of this classification system is needed. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.